NDLI: The impact of early phase price agreements on prices of orphan drugs

Content Provider	Springer Nature : BioMed Central
Author	Nuijten, Mark Van Wilder, Philippe
Abstract	Background Innovative orphan drugs often have an incremental cost-effectiveness ratio (ICER) which is higher than the maximum threshold for reimbursement. Payers have limited budgets and often cannot pay the full price of a new product, but pharmaceutical and biotechnology companies require a minimum price to satisfy their investors. The objective of this study was to present a possible solution to bridge this pricing gap by having early phase price agreements, which reduce the risk for investors. Methods We used a Pricing Model, which determines the minimum (break-even) price of an innovative drug from an investor’s perspective. This model is based on economic valuation theory, which uses the expected free cash flows and the required cost of capital. We selected two orphan drugs with a positive clinical assessment and an ICER higsher than the Dutch maximum threshold of €80,000 per QALY gained to use as examples in the model: Spinraza for spinal muscular atrophy and Orkambi for cystic fibrosis. RESULTS: The results show that early pricing agreements before phase III trials can substantially lower the drug price resulting from a lower cost of capital. The minimum price for orphan drugs can be reduced by 27.4%, when cost of capital decreases from 12 to 9%. An additional adjustment of other critical parameters due to early pricing agreements (lower probabilities of phase III failure and lower research and development (R&D) costs) can further reduce the minimal price by 62.8%. Conclusion This study shows that earlier timing of price negotiations resulting in an agreement on drug price can substantially lower the minimal price of orphan drugs for the investor.
Related Links	https://bmchealthservres.biomedcentral.com/counter/pdf/10.1186/s12913-021-06208-7.pdf
Ending Page	8
Page Count	8
Starting Page	1
File Format	HTM / HTML
ISSN	14726963
DOI	10.1186/s12913-021-06208-7
Journal	BMC Health Services Research
Issue Number	1
Volume Number	21
Language	English
Publisher	BioMed Central
Publisher Date	2021-03-12
Access Restriction	Open
Subject Keyword	Public Health Health Administration Health Informatics Nursing Research Drug price Cost-effectiveness Budget impact Economic valuation
Content Type	Text
Resource Type	Article
Subject	Health Policy

Sl.	Authority	Responsibilities	Communication Details
1	Ministry of Education (GoI), Department of Higher Education	Sanctioning Authority	https://www.education.gov.in/ict-initiatives
2	Indian Institute of Technology Kharagpur	Host Institute of the Project: The host institute of the project is responsible for providing infrastructure support and hosting the project	https://www.iitkgp.ac.in
3	National Digital Library of India Office, Indian Institute of Technology Kharagpur	The administrative and infrastructural headquarters of the project	Dr. B. Sutradhar bsutra@ndl.gov.in
4	Project PI / Joint PI	Principal Investigator and Joint Principal Investigators of the project	Dr. B. Sutradhar bsutra@ndl.gov.in Prof. Saswat Chakrabarti will be added soon
5	Website/Portal (Helpdesk)	Queries regarding NDLI and its services	support@ndl.gov.in
6	Contents and Copyright Issues	Queries related to content curation and copyright issues	content@ndl.gov.in
7	National Digital Library of India Club (NDLI Club)	Queries related to NDLI Club formation, support, user awareness program, seminar/symposium, collaboration, social media, promotion, and outreach	clubsupport@ndl.gov.in
8	Digital Preservation Centre (DPC)	Assistance with digitizing and archiving copyright-free printed books	dpc@ndl.gov.in
9	IDR Setup or Support	Queries related to establishment and support of Institutional Digital Repository (IDR) and IDR workshops	idr@ndl.gov.in

Pricing of orphan drugs in oncology and rare diseases.

The impact of patent expiry on drug prices: insights from the Dutch market.

An integrated valuation model for payer and investor.

Cost-effectiveness and budget impact of the management of uncomplicated urinary tract infection by community pharmacists

Cost-effectiveness and budget impact analysis of peritoneal dialysis and haemodialysis in South Africa

Cost-effectiveness and budget impact of heat-stable carbetocin compared to oxytocin and misoprostol for the prevention of postpartum hemorrhage (PPH) in women giving birth in India

Cancer drug funding decisions in Scotland: impact of new end-of-life, orphan and ultra-orphan processes

A proportional rule for setting reimbursement prices of new drugs and its mathematical consistency

Modelling the cost-effectiveness and budget impact of pay-for-performance programs in health care

The impact of early phase price agreements on prices of orphan drugs

Similar Documents

Pricing of orphan drugs in oncology and rare diseases.

The impact of patent expiry on drug prices: insights from the Dutch market.

An integrated valuation model for payer and investor.

Cost-effectiveness and budget impact of the management of uncomplicated urinary tract infection by community pharmacists

Cost-effectiveness and budget impact analysis of peritoneal dialysis and haemodialysis in South Africa

Cost-effectiveness and budget impact of heat-stable carbetocin compared to oxytocin and misoprostol for the prevention of postpartum hemorrhage (PPH) in women giving birth in India

Cancer drug funding decisions in Scotland: impact of new end-of-life, orphan and ultra-orphan processes

A proportional rule for setting reimbursement prices of new drugs and its mathematical consistency

Modelling the cost-effectiveness and budget impact of pay-for-performance programs in health care

The impact of early phase price agreements on prices of orphan drugs